Dr. Penelope Drake is the Director of R&D at Catalent Biologics (formerly Redwood Bioscience) where she oversees the preclinical development of antibody-drug conjugate programs. Her work encompasses aspects of target selection, antibody development, linker/payload optimization, in vitro and in vivo proof-of-concept studies—including efficacy and tolerability assessments, and exploration of next-generation compositions. In this task, she leverages a broad educational background rooted in immunology and anatomy (graduate work), glycobiology and hematopoietic development (postdoctoral work), and mass spectrometry/analytics (early academic-centered career).
Dr. Drake was recruited to Redwood Bioscience in 2011 to build the Analytical Group and has been with the company since then, through the acquisition by Catalent Biologics in 2014. She received a Ph.D. in Biochemistry from UCSF under the mentorship of Dr. Susan Fisher, followed by a postdoctoral fellowship at the University of California Berkeley in the laboratory of Dr. Carolyn Bertozzi. Penelope Drake graduated Magna Cum Laude with Phi Beta Kappa from the University of Iowa, earning B.S. (Botany) and B.A. (French) degrees. She is an author on over 25 peer-reviewed publications and several book chapters.